CY1112490T1 - Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως - Google Patents

Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως

Info

Publication number
CY1112490T1
CY1112490T1 CY20111101189T CY111101189T CY1112490T1 CY 1112490 T1 CY1112490 T1 CY 1112490T1 CY 20111101189 T CY20111101189 T CY 20111101189T CY 111101189 T CY111101189 T CY 111101189T CY 1112490 T1 CY1112490 T1 CY 1112490T1
Authority
CY
Cyprus
Prior art keywords
vaccines
stabilizers
freeze
immunogens
canine
Prior art date
Application number
CY20111101189T
Other languages
English (en)
Inventor
Delphine Magali Belin-Poput
Noel Yves Henri Jean Genin
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Limited filed Critical Merial Limited
Publication of CY1112490T1 publication Critical patent/CY1112490T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται γενικά στα πεδία της ανοσολογίας και της τεχνολογίας εμβολίων. Ειδικότερα, η παρούσα εφεύρεση αναφέρεται σε σταθεροποιητές για συνθέσεις ξηρανθείσες δια καταψύξεως ανοσογόνων και/ή εμβολίων ζωντανών εξασθενημένων μικροοργανισμών, που μπορεί να περιλαμβάνουν, μεταξύ άλλων, παραμυξοϊό κυνοειδών. Η εφεύρεση αναφέρεται περαιτέρω σε σταθεροποιημένες, συνθέσεις ξηρανθείσες δια καταψύξεως ανοσογόνων και/ή εμβολίων ζωντανών εξασθενημένων μικροοργανισμών, για παράδειγμα, παραμυξοϊού κυνοειδών, που μπορεί να περιέχουν αυτούς τους σταθεροποιητές. Οι άλλες όψεις της εφευρέσεως περιγράφονται στην ή είναι εμφανείς από την ακόλουθη αποκάλυψη, και είναι εντός του πεδίου της εφευρέσεως.
CY20111101189T 2005-09-16 2011-12-02 Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως CY1112490T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71764005P 2005-09-16 2005-09-16
EP06814694A EP1954308B1 (en) 2005-09-16 2006-09-15 Stabilizers for freeze-dried vaccines

Publications (1)

Publication Number Publication Date
CY1112490T1 true CY1112490T1 (el) 2015-12-09

Family

ID=37808009

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101189T CY1112490T1 (el) 2005-09-16 2011-12-02 Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως

Country Status (15)

Country Link
US (1) US8784843B2 (el)
EP (1) EP1954308B1 (el)
JP (1) JP5275803B2 (el)
CN (1) CN101312742B (el)
AT (1) ATE523207T1 (el)
CY (1) CY1112490T1 (el)
DK (1) DK1954308T3 (el)
ES (1) ES2373238T3 (el)
HR (1) HRP20110803T1 (el)
ME (1) ME01965B (el)
PL (1) PL1954308T3 (el)
PT (1) PT1954308E (el)
RS (1) RS51996B (el)
SI (1) SI1954308T1 (el)
WO (1) WO2007035455A2 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JP5214464B2 (ja) 2005-12-28 2013-06-19 アドバンスド バイオニュートリション コーポレーション 多糖類、糖類およびポリオール類の乾燥マトリックスを含む、ガラス形態の、プロバイオティクス細菌用送達媒体およびその製造方法
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
GB2451216B (en) * 2006-05-12 2011-05-04 Bharat Biotech Int Ltd A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
CN101903041A (zh) * 2007-12-21 2010-12-01 辉瑞大药厂 经热处理的菌苗,及由这些经热处理的菌苗制备的乳剂疫苗
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EP2391713A1 (en) * 2009-01-30 2011-12-07 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
JP5841527B2 (ja) 2009-05-26 2016-01-13 アドバンスド バイオニュートリション コーポレーション 生物学的に活性な微生物および／または生物活性材料を含む安定な乾燥粉末組成物およびその製造方法
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
CN102725393B (zh) 2010-01-28 2015-12-02 先进生物营养公司 包含生物活性材料的干燥玻璃质组合物
EP2552478B1 (en) 2010-03-31 2016-12-21 Stabilitech Ltd. Excipients for stabilising viral particles
JP5960120B2 (ja) * 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
EP2558120A4 (en) 2010-04-15 2013-08-28 Shin Nippon Biomedical Lab Ltd METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION
SG187250A1 (en) 2010-08-13 2013-03-28 Advanced Bionutrition Corp Dry storage stabilizing composition for biological materials
JP5933565B2 (ja) * 2010-10-15 2016-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
CN102228687B (zh) * 2011-06-24 2012-10-10 浙江普康生物技术股份有限公司 不含明胶、人血白蛋白保护剂的冷冻干燥甲型肝炎减毒活疫苗及制备方法
SI2734230T1 (sl) * 2011-07-20 2019-04-30 Merial Limited Rekombinantno cepivo proti virusu mačje levkemije, ki vsebuje optimiziran gen ovojnice virusa mačje levkemije
HUE035774T2 (en) * 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
CN102488894B (zh) * 2011-12-31 2014-08-20 齐鲁动物保健品有限公司 一种狐狸脑炎活疫苗及其制备方法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
CN102854313A (zh) * 2012-09-29 2013-01-02 黑龙江省农业科学院植物脱毒苗木研究所 马铃薯y病毒阳性对照品的制备方法
CN102920669A (zh) * 2012-11-09 2013-02-13 湖北凤凰白云山药业有限公司 一种甘露醇冻干粉的制备方法
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
CA2923010C (en) 2013-09-03 2022-08-30 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
EP3057978B1 (en) 2013-10-16 2022-09-14 Merck Sharp & Dohme LLC Method of microwave vacuum drying spherical-shaped pellets of biological materials
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
FR3034418B1 (fr) * 2015-04-03 2018-09-28 Roquette Freres Utilisation de combinaisons particulieres de carbohydrates pour stabiliser des proteines, et compositions proteiques contenant de telles combinaisons
DK3328215T3 (da) 2015-07-29 2021-09-13 Advanced Bionutrition Corp Stabilt tørre probiotiske sammensætninger til særlige kostanvendelser
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
NL2018155B1 (en) 2017-01-11 2018-07-25 Intervet Int Bv Oral vaccine against ruminant respiratory disease
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP3801469A4 (en) * 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. KIT OF CRITICAL REAGENTS IN THE FORM OF LYOSPHERES
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
CN117664682A (zh) * 2020-06-15 2024-03-08 深圳市瑞赛生物技术有限公司 即用型维生素标准品及其制备方法、使用方法和贮存稳定剂
CN112057603B (zh) * 2020-07-25 2023-07-14 艾美卫信生物药业（浙江）有限公司 一种白喉毒素无毒突变体crm197蛋白的冻干方法
CN115624630A (zh) * 2022-12-19 2023-01-20 北京荷牧生物科技有限公司 冻干保护组合物及其应用和基于该组合物的核酸脂质纳米颗粒冻存方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108956A (en) * 1964-05-26 1968-04-10 Ciba Ltd Process for the manufacture of bcg vaccines
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
JPS4840990A (el) * 1971-10-04 1973-06-15
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS6281327A (ja) * 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH07121871B2 (ja) * 1986-10-09 1995-12-25 国立予防衛生研究所長 インフルエンザワクチン凍結乾燥製剤
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5147756A (en) * 1991-04-11 1992-09-15 E. I. Du Pont De Nemours And Company Stabilized, aqueous hydrazide solutions for photographic elements
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
JPH08176011A (ja) * 1994-12-21 1996-07-09 Dot:Kk 無菌性骨壊死症候群治療剤
JP3193057B2 (ja) * 1995-03-17 2001-07-30 久光製薬株式会社 遺伝子導入製剤
US5869306A (en) * 1995-03-17 1999-02-09 Hisamitsu Pharmaceutical Co., Inc. Gene transfer preparation
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
JP2003502345A (ja) * 1999-06-10 2003-01-21 メリアル ペットまたはスポ−ツ用動物のためのｄｎａワクチン
JP2002326924A (ja) * 2001-05-07 2002-11-15 Hayashibara Biochem Lab Inc 洗顔料
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions

Also Published As

Publication number Publication date
EP1954308B1 (en) 2011-09-07
PT1954308E (pt) 2011-11-03
JP2009508866A (ja) 2009-03-05
ME01965B (me) 2012-04-30
RS51996B (en) 2012-04-30
ATE523207T1 (de) 2011-09-15
EP1954308A2 (en) 2008-08-13
PL1954308T3 (pl) 2012-01-31
WO2007035455A2 (en) 2007-03-29
US20100260796A1 (en) 2010-10-14
HRP20110803T1 (hr) 2011-11-30
DK1954308T3 (da) 2011-10-24
WO2007035455A3 (en) 2007-07-26
US8784843B2 (en) 2014-07-22
CN101312742A (zh) 2008-11-26
CN101312742B (zh) 2012-07-25
SI1954308T1 (sl) 2011-12-30
ES2373238T3 (es) 2012-02-01
JP5275803B2 (ja) 2013-08-28

Similar Documents

Publication Publication Date Title
CY1112490T1 (el) Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως
CY1118958T1 (el) Μεθοδοι και συνθεσεις για ζωντανους εξασθενημενους ιους
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1122646T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
CY1120739T1 (el) Αντισωματα αντι-il-6, συνθεσεις, μεθοδοι και χρησεις
CY1118090T1 (el) Αντιγονα ανασυνδυασμενου rsv
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
EA201791541A3 (ru) Композиции и способы контроля нематод
ATE491471T1 (de) Adjuvantien für dns impstoffe basierend auf imidazochinoline
CY1114916T1 (el) Μεθοδοι
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1116383T1 (el) Αντιβακτηριακες ενωσεις
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1109149T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK2079481T3 (da) Vaccinepeptidkombinationer mod katteallergi
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
BR112013005136A2 (pt) composições e métodos para controlar pragas de nematodeo
CY1114820T1 (el) Νεες ανοσοενισχυτικες ενωσεις βασιζομενες σε φλαγκελλινη και χρηση αυτων
CY1113076T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CR11434A (es) Anticuerpos anti-amiloide humanos; composiciones, metodosy usos
DK1881845T3 (da) Nipah-virusvacciner
DK1833465T3 (da) Lyofilisering af virosomer
ATE427117T1 (de) Verwendung nativer peptide und deren optimierter derivate zur impfung